NCT06056336View on ClinicalTrials.gov

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 7, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2026

Conditions
Esophageal Squamous Cell CarcinomaNeoadjuvant ChemoimmunotherapyAdjuvant Therapy
Interventions
DRUG

Tislelizumab

Tislelizumab 200 mg q21d up to 1 year. Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles. Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.

Trial Locations (1)

Unknown

RECRUITING

Shanghai chest hospital, Shanghai

All Listed Sponsors
lead

Guo Xufeng

OTHER